PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·PELOSI, NANCY BUYNVDA$500K–$1M·TUBERVILLE, TOMMY BUYMSFT$50K–$100K·CRENSHAW, DAN SELLXOM$15K–$50K·
← Leaderboard
PODD
Ticker

PODD

Congressional Trades
8
by 2 members
Buys
2
25%
Sells
3
38%
Total Volume
$565K
midpoint
Unique Traders
2
members

Party Breakdown

Democrats8 · 100%
Republicans0 · 0%

Party Trading Divergence

Democrat vs. Republican buy / sell pressure by monthMODERATE

Bar length = total trades. Color = net sentiment — green = net buying, red = net selling. Months with no activity hidden.

Democrat ←
Month
→ Republican
02
Apr '24
02
Nov '24
1
Aug '25
11
Feb '26
Democrats25Net sellers
vs
Republicans00Neutral
Net buyingNet selling⚡ Party split

💼 Lobbying Filings

all →
  • 2026-04-20$140K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to talks of future budget reconciliation package. Issues related to the reintroduction of the DIABETES Act (S.4037) in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade and the Sec. 232 Tariff investigation related to Medical Devices. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to durable infusion insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plan
  • 2026-04-20$60K
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2026-01-19$140K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to National Coverage Determination revisions specifically in reference to insulin pumps. Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Is
  • 2026-01-17$50K
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2025-10-17$110K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act. Issues related to CMS notice of proposed rule, DMEPOS Home Health Rule.
  • 2025-10-12$50K
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2025-07-30$40K
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2025-07-21$130K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM). Issues related to Prior Authorizations in Medicare Advantage plans. Issues related to support of Improving Seniors' Timely Access to Care Act.
  • 2025-07-21$0
    INSULET CORPORATION
    General education on diabetes care. General education about Insulet.
  • 2025-04-17$40K
    INSULET CORPORATION
    Issues related to the disease of diabetes, diabetes therapies, automated insulin delivery devices, and management of the disease of diabetes. Issues related to medical devices and medical device technologies. Issues related to Pharmacy Benefit Manager (PBM) reform proposals, PBM transparency and potential PBM proposals related to budget reconciliation package. Issues related to the reintroduction or possible reintroduction of the DIABETES Act in the 119th Congress. Issues related to artificial intelligence (AI) and predictive algorithms in medical devices and medical device technology. Issues related to tariffs and trade. Issues related to Local Coverage Determination revisions specifically in pathways for Continuous Glucose Monitors (CGM).

Congressional Momentum

buy vs. sell pressureNEUTRAL

Score 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.

Last 30 Days
No trades
Last 90 Days
50
1 buy2 total1 sell
$8K buys · $8K sells
All-Time
3
2 buys8 total6 sells
$16K buys · $549K sells
Cumulative Net Position (buy vol − sell vol)
-$533K
2020-038 trades plotted2026-02

Trade Activity Timeline

Congressional buys & sells by month · last 5 months w/ activity

20/03
24/04
24/11
25/08
26/02
BuysSellsOtherHigh-volume month

Who Moved First

each row = one member · sorted by earliest disclosed trade
1 buyers ·2 sellers
202420252026DTina Smith3×2020-03-17 · partial_sell · $375K2024-04-04 · partial_sell · $75K2024-04-04 · partial_sell · $75KDRo Khanna5×2024-11-12 · sell · $8K2024-11-15 · sell · $8K2025-08-04 · buy · $8K2026-02-17 · buy · $8K2026-02-24 · sell · $8K
BuySellOtherDot size ∝ trade size · top 2 most-active traders shown

All Disclosed Trades

DateMemberActionAmountFiling Delay
2026-02-24DRo KhannaSELL$1K – $15K13d
2026-02-17DRo KhannaBUY$1K – $15K20d
2025-08-04DRo KhannaBUY$1K – $15K36d
2024-11-15DRo KhannaSELL$1K – $15K20d
2024-11-12DRo KhannaSELL$1K – $15K23d
2024-04-04DTina SmithPARTIAL_SELL$50K – $100K16d
2024-04-04DTina SmithPARTIAL_SELL$50K – $100K15d
2020-03-17DTina SmithPARTIAL_SELL$250K – $500K1259d